The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Tamoxifen (ICI46,474) as a targeted therapy to treat and prevent breast cancer
Open accessAbstract
Antihormonal therapy targeted to the oestrogen receptor (OER) is recognized as a significant advance in the treatment and prevention of breast cancer. However, the research method used to achieve the current successes seen in the clinic was not linear but was based on the changing fashions in research and the application of appropriate testing models. The discovery and investigation of nonsteroidal antioestrogens by the pharmaceutical industry during the 1960s was initially an exciting prospect for clinical development. The drugs were superb antifertility agents in laboratory animals, so the prospect of marketing a ‘morning after’ pill was a high priority. Unfortunately, the reproductive endocrinology of the rat was found to be completely different from that of the human. Antioestrogens, in fact, improved fertility by inducing ovulation in subfertile women so much of the drug development was discontinued. The successful reinvention of ICI46,474 from its origins as a failed contraceptive to a pioneering breast cancer treatment targeted to the OER presaged the development of the current menu of medicines targeted to a range of different survival mechanisms in cancer cells. British Journal of Pharmacology (2006) 147, S269–S276. doi:10.1038/sj.bjp.0706399
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Fisher, B., Costantino, J. P., Wickerham, D. L., Redmond, C. K., Kavanah, M., Cronin, W. M., Vogel, V., Robidoux, A., Dimitrov, N., Atkins, J., et al. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.18.1371 · Cited by 5,485
Tamoxifen for early breast cancer: an overview of the randomised trials
(1998) · The Lancet · doi:10.1016/s0140-6736(97)11423-4 · Cited by 4,085
Molecular basis of agonism and antagonism in the oestrogen receptor
Brzozowski, A. M., Pike, A. C. W., Dauter, Z., Hubbard, R. E., Bonn, T., Engström, O., Öhman, L., Greene, G. L., Gustafsson, J.-Å., & Carlquist, M. (1997) · Nature · doi:10.1038/39645 · Cited by 3,355
Cummings, S. R., Eckert, S., Krueger, K. A., Grady, D., Powles, T. J., Cauley, J. A., Norton, L., Nickelsen, T., Bjarnason, N. H., Morrow, M., et al. (1999) · JAMA · doi:10.1001/jama.281.23.2189 · Cited by 1,872
Self-citationGoss, P. E., Ingle, J. N., Martino, S., Robert, N. J., Muss, H. B., Piccart, M. J., Castiglione, M., Tu, D., Shepherd, L. E., Pritchard, K. I., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa032312 · Cited by 1,795
Coombes, R. C., Hall, E., Gibson, L. J., Paridaens, R., Jassem, J., Delozier, T., Jones, S. E., Alvarez, I., Bertelli, G., Ortmann, O., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040331 · Cited by 1,759
Beatson, G. (1896) · The Lancet · doi:10.1016/s0140-6736(01)72384-7 · Cited by 1,608
Beatson, G. (1896) · The Lancet · doi:10.1016/s0140-6736(01)72307-0 · Cited by 1,282
Effects of Tamoxifen on Bone Mineral Density in Postmenopausal Women with Breast Cancer
Love, R. R., Mazess, R. B., Barden, H. S., Epstein, S., Newcomb, P. A., Jordan, V. C., Carbone, P. P., & DeMets, D. L. (1992) · New England Journal of Medicine · doi:10.1056/nejm199203263261302 · Cited by 1,129
Self-citationHowell, A. (1998) · PubMed · Cited by 901
Tamoxifen: a most unlikely pioneering medicine
Jordan, V. C. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1031 · Cited by 824
Self-citationCummings, S. R. (1999) · Medical Entomology and Zoology · Cited by 797
A New Anti-oestrogenic Agent in Late Breast Cancer: An Early Clinical Appraisal of ICI46474
Cole, M. P., Jones, C. T. A., & Todd, I. D. H. (1971) · British Journal of Cancer · doi:10.1038/bjc.1971.33 · Cited by 701
Effects of Raloxifene on Serum Lipids and Coagulation Factors in Healthy Postmenopausal Women
Walsh, B. W. (1998) · JAMA · doi:10.1001/jama.279.18.1445 · Cited by 692
Fisher, B., Dignam, J., Bryant, J., & Wolmark, N. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.9.684 · Cited by 635
Gordon, D. (1976) · The Lancet · doi:10.1016/s0140-6736(76)92329-1 · Cited by 552
The estrogen receptor: a model for molecular medicine.
Jensen, E. V., & Jordan, V. C. (2003) · PubMed · Cited by 470
Self-citationA NEW DERIVATIVE OF TRIPHENYLETHYLENE: EFFECT ON IMPLANTATION AND MODE OF ACTION IN RATS
HARPER, M. J. K., & WALPOLE, A. L. (1967) · Reproduction · doi:10.1530/jrf.0.0130101 · Cited by 445
Estrogen receptors and breast cancer response to adrenalectomy.
Jensen, E. V., Block, G. E., Smith, S. B., Kyser, K., & DeSombre, E. R. (1971) · PubMed · Cited by 423
Development of antiestrogens and their use in breast cancer: eighth Cain memorial award lecture.
Lerner, L. J., & Jordan, V. C. (1990) · PubMed · Cited by 417
Self-citationBiochemical pharmacology of antiestrogen action.
Jordan, V. C. (1984) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06650-5 · Cited by 417
Self-citationEffects of Tamoxifen on Cardiovascular Risk Factors in Postmenopausal Women
Love, R. R., Wiebe, D. A., Newcomb, P. A., Cameron, L., Leventhal, H., Jordan, V. C., Feyzi, J., & DeMets, D. L. (1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-115-11-860 · Cited by 374
Self-citationEffect of tamoxifen (ICI 46,474) on initiation and growth of DMBA-induced rat mammary carcinomata
Jordan, V. C. (1976) · European Journal of Cancer (1965) · doi:10.1016/0014-2964(76)90030-x · Cited by 371
Self-citationGottardis, M. M., & Jordan, V. C. (1987) · PubMed · Cited by 352
Self-citationEffects of anti-estrogens on bone in castrated and intact female rats
Jordan, V. C., Phelps, E., & Lindgren, J. U. (1987) · Breast Cancer Research and Treatment · doi:10.1007/bf01806132 · Cited by 324
Self-citationSelective estrogen receptor modulation
Jordan, V. C. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00059-5 · Cited by 315
Self-citationRadiation Therapy and Tamoxifen: Concurrent or Sequential? That Is the Question
Whelan, T., & Levine, M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.955 · Cited by 304
A current view of tamoxifen for the treatment and prevention of breast cancer
Jordan, V. C. (1993) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1993.tb13840.x · Cited by 299
Self-citationLønning, P. E., Geisler, J., Krag, L. E., Erikstein, B., Bremnes, Y., Hagen, A. I., Schlichting, E., Lien, E. A., Øfjord, E. S., Paolini, J., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.097 · Cited by 295
Powles, T., Hardy, Jr., Ashley, S., Farrington, G., Cosgrove, D., Davey, J., Dowsett, M., McKinna, J., Nash, A., Sinnett, H., et al. (1989) · British Journal of Cancer · doi:10.1038/bjc.1989.235 · Cited by 246
LERNER, L. J., HOLTHAUS, F. J., & THOMPSON, C. R. (1958) · Endocrinology · doi:10.1210/endo-63-3-295 · Cited by 233
Jordan, V. C., & Allen (née Naylor), K. E. (1980) · European Journal of Cancer (1965) · doi:10.1016/0014-2964(80)90156-5 · Cited by 214
Self-citationTamoxifen (ICI 46,474) and the human carcinoma 8S oestrogen receptor
Jordan, V. C., & Koerner, S. (1975) · European Journal of Cancer (1965) · doi:10.1016/0014-2964(75)90119-x · Cited by 186
Self-citationAromatase inhibitors: mechanism of action and role in the treatment of breast cancer
MILLER, W. (2003) · Seminars in Oncology · doi:10.1016/s0093-7754(03)00302-6 · Cited by 183
Suppression of Mouse Mammary Tumorigenesis by Long-Term Tamoxifen Therapy
Jordan, V. C., Lababidi, M. K., & Langan-Fahey, S. M. (1991) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/83.7.492 · Cited by 134
Self-citationMastro, L. D., & Venturini, M. (2005) · The Lancet · doi:10.1016/s0140-6736(05)74802-9 · Cited by 133
LUNAN, C. B., & Klopper, A. I. (1975) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1975.tb01568.x · Cited by 69
Effect of anti-oestrogens on initiation of mammary cancer in the female rat
Terenius, L. Y. (1971) · European Journal of Cancer (1965) · doi:10.1016/0014-2964(71)90096-x · Cited by 33
Cited by
Y. Maximov, P., M. Lee, T., & Craig Jordan, V. (2013) · Current Clinical Pharmacology · doi:10.2174/1574884711308020006 · Cited by 376
Jordan, V. C., & Brodie, A. M. H. (2007) · Steroids · doi:10.1016/j.steroids.2006.10.009 · Cited by 296
Self-citationWnt signaling in triple-negative breast cancer
Pohl, S.-G., Brook, N., Agostino, M., Arfuso, F., Kumar, A. P., & Dharmarajan, A. (2017) · Oncogenesis · doi:10.1038/oncsis.2017.14 · Cited by 296
Nuclear Receptors and Their Selective Pharmacologic Modulators
Burris, T. P., Solt, L. A., Wang, Y., Crumbley, C., Banerjee, S., Griffett, K., Lundasen, T., Hughes, T., & Kojetin, D. J. (2013) · Pharmacological Reviews · doi:10.1124/pr.112.006833 · Cited by 283
Tamoxifen a pioneering drug: An update on the therapeutic potential of tamoxifen derivatives
Shagufta, & Ahmad, I. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.11.056 · Cited by 263
Metadata
- Authors
- Jordan, V. C.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2006-01
- Volume
- 147
- Issue
- S1
- Pages
- S269-76
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W2134627266
- Cited by
- 292
- References
- 44
- FWCI
- 5.30
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.